Regeneron Pharmaceuticals Stock Book Value Per Share
| REGN Stock | USD 961.73 8.24 0.85% |
Regeneron Pharmaceuticals fundamentals help investors to digest information that contributes to Regeneron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Regeneron Stock. The fundamental analysis module provides a way to measure Regeneron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regeneron Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 243.42 | 255.59 | |
| Tangible Book Value Per Share | 233.69 | 245.37 |
Regeneron | Book Value Per Share |
Regeneron Pharmaceuticals Company Book Value Per Share Analysis
Regeneron Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Regeneron Pharmaceuticals Book Value Per Share | 244.93 X |
Most of Regeneron Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regeneron Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Regeneron Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Regeneron Pharmaceuticals is extremely important. It helps to project a fair market value of Regeneron Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Regeneron Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regeneron Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regeneron Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Regeneron Book Value Per Share Historical Pattern
Today, most investors in Regeneron Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Regeneron Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Regeneron Pharmaceuticals book value per share as a starting point in their analysis.
Regeneron Pharmaceuticals Book Value Per Share |
| Timeline |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Regeneron Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Regeneron Pharmaceuticals is about 244 times. This is 14507.53% lower than that of the Biotechnology sector and 198.51% lower than that of the Health Care industry. The book value per share for all United States stocks is 87.32% higher than that of the company.
Regeneron Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regeneron Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regeneron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics of similar companies.Regeneron Pharmaceuticals is currently under evaluation in book value per share category among related companies.
Regeneron Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regeneron Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regeneron Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Regeneron Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0774 | ||||
| Profit Margin | 0.29 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 97.81 B | ||||
| Shares Outstanding | 108.37 M | ||||
| Shares Owned By Insiders | 1.69 % | ||||
| Shares Owned By Institutions | 89.02 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Earning | 15.51 X | ||||
| Price To Book | 3.82 X | ||||
| Price To Sales | 7.57 X | ||||
| Revenue | 13.12 B | ||||
| Gross Profit | 7.02 B | ||||
| EBITDA | 4.05 B | ||||
| Net Income | 3.95 B | ||||
| Cash And Equivalents | 7.02 B | ||||
| Cash Per Share | 65.75 X | ||||
| Total Debt | 2.7 B | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.36 X | ||||
| Book Value Per Share | 244.93 X | ||||
| Cash Flow From Operations | 4.59 B | ||||
| Short Ratio | 3.05 X | ||||
| Earnings Per Share | 33.84 X | ||||
| Price To Earnings To Growth | 1.46 X | ||||
| Target Price | 1052.64 | ||||
| Number Of Employees | 13.68 K | ||||
| Beta | 0.14 | ||||
| Market Capitalization | 105.63 B | ||||
| Total Asset | 33.08 B | ||||
| Retained Earnings | 27.26 B | ||||
| Working Capital | 16.06 B | ||||
| Current Asset | 2.92 B | ||||
| Current Liabilities | 811.16 M | ||||
| Net Asset | 33.08 B |
About Regeneron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regeneron Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Altman Z Score analysis. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share 33.84 | Revenue Per Share 122.574 | Quarterly Revenue Growth (0.01) | Return On Assets 0.0774 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.